Social, ethical and legal considerations raised by the discovery and patenting of the BRCA1 and BRCA2 genes

New Genetics and Society

Volumn 33, Issue 2, 2014, Pages 167-180

  Joly, Yann ^a   Tonin, Patricia N ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

BRCA1 and BRCA2; Myriad; Patent

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; COURT; DECISION MAKING; ETHICS; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; GENETICS; LEGAL ASPECT; MOLECULAR DIAGNOSIS; OVARY CANCER; PATENT; PRIORITY JOURNAL; SOCIAL ASPECT; TUMOR SUPPRESSOR GENE;

EID: 84900991950     PISSN: 14636778     EISSN: 14699915     Source Type: Journal    
DOI: 10.1080/14636778.2014.914849     Document Type: Article

References (33)

1. Association for Molecular Pathology v. United States PTO, 702 F. Supp. 2d 181, 2010
2. Association for Molecular Pathology v. United States PTO, 653 F.3d 1329, 2011
3. Association for Molecular Pathology v. United States PTO, 689 F.3d 1303, 2012
4. Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 12-398, 2013
5. Cancer Voices Australia v Myriad Genetics Inc, Federal Court of Australia, 65 at 46-53, 2013
6. Carvalho, M. A., F. J. Couch, and A. N. A. Monteiro. 2007. "Functional Assays for BRCA1 and BRCA2." International Journal of Biochemistry & Cell Biology 39 (2): 398-310
7. Cook-Deegan, R., J. M. Conley, J. P. Evans, and D. Vorhaus. 2013. "The Next Controversy in Genetic Testing: Clinical Data as Trade Secrets & Quests." European Journal of Human Genetics 21 (6), 585-588
8. Diamond v. Chakrabarty, 447 U.S. 303, 1980
9. Gold, E. R., and J. Carbone. 2010. "Myriad Genetics: In the Eye of the Policy Storm." Genetics in Medicine 12 (4): S39-S70
10. Hall, H., M. K. Lee, B. Newman, J. E. Morrow, L. A. Anderson, B. Huey, and M. C. King. 1990."Linkage of Early-onset Familial Breast Cancer to Chromosome 17q21." Science 250 (4988): 1684-1689. (Pubitemid 120031871
11. Holman, C. M. 2013. "In Myriad the Supreme Court has, Once Again Increased the Uncertainty of US Patent Law." Biotechnology Law Report
12. Joly, Y. 2007. "Open Source Approaches in Biotechnology: Utopia Revisited." Maine Law Review 59 (2): 385-405
13. Matthijs, G., I. Huys, G. Van Overwalle, and D. Stoppa-Lyonnet. 2013. "The European BRCA Patent Oppositions and Appeals: Coloring Inside the Lines." Nature Biotechnology 31 (8): 704-710
14. Miki, Y., J. Swenson, D. Shattuck-Eidens, P. A. Futreal, K. Harshman, S. Tavtigian, Q. Lui, et al. 1994. "A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1." Science 266 (5182): 66-71. (Pubitemid 24345325
15. Modell, S. M., S. B. King, T. Citrin, and S. L. Kardia. 2014. "Phase Changes in the BRCA Policy Domain." Journal of Religion and Health 53 (3): 715-724
16. Moghadasi, S., N. Hofland, J. N. Wouts, F. B. L. Hogervorst, J. T. Wijnen, M. P. G. Vreeswijk, and C. J. van Asperen. 2013. "Variants of Uncertain Significance in BRCA1 and BRCA2 Assessment of in Silico Analysis and a Proposal for Communication in Genetic Counselling." Journal of Medical Genetics 50 (2): 74-79
17. Narod, S. A., J. Feunteun, H. T. Lynch, P. Watson, T. Conway, J. Lynch, and G. M. Lenoir. 1991. "Familial Breast-ovarian Cancer Locus on Chromosome 17q12-q23." Lancet 338 (8759): 82-83
18. NASDAQ. 2013. Myriad Genetics Inc, Stock Chart 02/1/13 to 12/1/13 from NASDAQ database
19. National Cancer Institute. 2014. PDQw Genetics of Breast and Ovarian Cancer. Bethesda, MD: National Cancer Institute. Date last modified 06/07/2013. Accessed June 27. http://cancer.gov/cancertopics/pdq/genetics/breast-and- ovarian/HealthProfessional
20. Oros, K. K., P. Ghadirian, C. M. Greenwood, C. Perret, Z. Shen, Y. Paredes, S. L. Arcand, et al. 2004
21. "Significant Proportion of Breast and/or Ovarian Cancer Families of French Canadian descent Harbor 1 of 5 BRCA1 and BRCA2 Mutations." International Journal of Cancer 112 (3): 411-419
22. Phillippidis, A. 2013. "Gene Test Boom Faces Lawsuits." Genetic Engineering & Biotechnology News 33 (16). http://online.liebertpub.com/doi/ full/10.1089/gen.33.16.01
23. Ray, Turna. 2013. "Not Backing Down in BRCATest Infringement Case, Ambry Slaps Myriad with Antitrust Countersuit." Genome Web, August 7
24. Ray, Turna. 2014. "USPTO Guidance on Patent Eligibility of Products Derived from Nature Raises Industry Concerns." Genome Web, April 23
25. Rosenthal, E. 2013. "Proliferation of Marketing Information at SABCS about New Commercial BRCA Testing." Oncology Times, December 12
26. Scudellari, M. 2013. "Myriad Sues Developers of Competing Breast Cancer Tests." Nature Medicine 19 (8): 948-948
27. So, D., and Y. Joly. 2013. "Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga." Current Pharmacogenomics and Personalized Medicine 11 (2): 98-109
28. Stauber, R. B. 2014. "A Natural Disagreement: Markedly Different Views on the Patentability of Human Genes, as Presented in the Case History and Recent Supreme Court Decision in Myriad Genetics." Biotechnology Law Report 33 (2): 61-80
29. Tavtigian, S. V., J. Simard, J. Rommens, F. Couch, D. Shattuck-Eidens, S. Neuhausen, S. Merajver, et al. 1996. "The Complete BRCA2 Gene and Mutations in Chromosome 13q-linked Kindreds." Nature Genetics 12 (3): 333-337. (Pubitemid 26080098
30. Tonin, P., B. Weber, K. Offit, F. Couch, T. R. Rebbeck, S. Neuhausen, A. K. Godwin, et al. 1996. "Frequency of Recurrent BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Breast Cancer Families." Nature Medicine 2 (11): 1179-1183. (Pubitemid 26375392
31. Williams-Jones, B., and J. E. Graham. 2003. "Actor-Network Theory: A Tool to Support Ethical Analysis of Commercial Genetic Testing." New Genetics and Society 22 (3): 271-296. (Pubitemid 38167927
32. Wooster, R., G. Bignell, J. Lancaster, S. Swift, S. Gregory, C. Gumbs, G. Micklem, et al. 1995. "Identification of the Breast Cancer Susceptibility Gene BRCA2." Nature 378 (6559): 789-792. (Pubitemid 26004412
33. Wooster, R., S. L. Neuhausen, J. Mangion, Y. Quirk, D. Ford, N. Collins, K. Nguyen, et al. 1994. "Localization of a Breast Cancer Susceptibility Gene, BRCA2, to Chromosome 13q12-13." Science 265 (5181): 2088-2090. (Pubitemid 24325690